ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Food and Drug Administration has approved the first all-oral treatment for sleeping sickness, a parasitic disease that mostly affects people living in rural sub-Saharan Africa. The treatment, fexindazole, was developed by Sanofi and the Drugs for Neglected Diseases Initiative (DNDi). European regulators approved it in 2018. With the FDA’s nod, DNDi gets a voucher for early review of another drug. In the past, such vouchers have sold for as much as $350 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X